ENGN Stock — enGene Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are developing non-viral genetic medicines based on our novel and proprietary dually derived chitosan, or “DDX”, gene delivery platform, which allows localized delivery of complex genetic cargos directly to mucosal tissues and other organs. Our lead product candidate, detalimogene voraplasmid, or detalimogene, formerly known as EG-70, is a therapy designed to promote a pro-inflammatory, anti-tumor microenvironment throughout the bladder urothelium.

Source: 10-K FY2025 via SEC EDGAR

Share price

$1.75

Market cap

$117.3M

Cash

$266.3M

Enterprise value

-$149.0M

Balance sheet

Cash	$266.3M
Debt	$0.0M
Net cash	$266.3M
Enterprise value	-$149.0M
Basic shares	67.0M shares
Fully diluted shares	93.2M shares
Fully diluted market cap	$163.1M
Cash per share	$3.97
Quarterly burn	$18.9M
Cash runway	14.1 quarters

Cash figures as of 2026-07-31. Database snapshot: 2026-11-07.

Share structure

Common

67.0M

Pre-funded warrants

2.7M

Options

12.5M

RSUs

0.4M

Warrants

8.6M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

2.0M

FDSO

93.2M

Cap table as of 2026-07-31.

Price history

Loading ENGN daily closes…

Loading price history…

Next catalyst

detalimogene · Est. Nov 15, 2026 · quarter midpoint · guided Now

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
GUIDEDEst. Nov 15, 2026 Now quarter midpoint	detalimogene LEGEND Cohort 1	Not disclosed	LEGEND Cohort 1	Q4 2026
GUIDEDEst. Jul 2, 2027 in 8 wks guidance midpoint	detalimogene	Not disclosed	Not disclosed	2027
Jun 11 - Jul 23 in 19 mo	EG-70 (phase 1)	Phase 1/2	Superficial Bladder Cancer; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Non-muscle Invasive Bladder Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

detalimogene

Phase 2 · Active Modality: genetic medicine (DDX non-viral gene delivery platform); dual RIG-I agonist

Aliases EG-70, detalimogene voraplasmid

Target RIG-I

Partnerships Nature Technology Corporation: non-exclusive Nanoplasmid license (Apr 2020). Company retains all development and commercialization rights to detalimogene

Indications

High-risk BCG-unresponsive NMIBC with CIS (pivotal) (Phase 2)
BCG-naive NMIBC with CIS (Phase 2)
BCG-exposed NMIBC with CIS (Phase 2)
BCG-unresponsive papillary-only NMIBC (no CIS) (Phase 2)

Catalysts

— Q4 2026

Status note Lead product candidate. LEGEND (NCT04752722): combined Phase 1/2 open-label; Cohort 1 pivotal enrolled 125 patients with high-risk BCG-unresponsive NMIBC with CIS (enrollment complete). Cohort 2b (45 enrolled as of Nov 11, 2025); Cohort 3 (36 enrolled). FDA RMAT and Fast Track designations.

Per-asset detail extracted from the 10-Q filed 2026-09-08. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	EG-70 (phase 1)
Lead indication	Superficial Bladder Cancer; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Non-muscle Invasive Bladder Cancer
Lead phase	Phase 1/2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04752722	Phase 1/2	Recruiting	Sponsor	enGene, Inc.	—	Superficial Bladder Cancer; Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Non-muscle Invasive Bladder Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for enGene, Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
Perceptive Advisors	4,822,169	+4,822,169	0.13%	2026-08-14
ADAR1 Capital Management	2,104,986	+2,104,986	0.17%	2026-08-14
BVF Partners	945,402	+945,402	0.01%	2026-08-14
DAFNA Capital	74,650	+74,650	0.02%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

ENGN — enGene Therapeutics Inc. ☆